Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Saturday, September 30, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2023 (2023-09-30): -59.94%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-9.37%
RETURN ON EQUITY (ROE) AVG 3Y
-9.48%
RETURN ON EQUITY (ROE) AVG 5Y
-168.40%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cartesian Therapeutics, Inc.
Market Cap
$203.92M
Return on Equity (ROE)
N/A
TTM Avg
-9.37%
3Y Avg
-9.48%
5Y Avg
-168.40%
Market Cap
$202.26M
Return on Equity (ROE)
N/A
TTM Avg
213.11%
3Y Avg
66.34%
5Y Avg
24.75%
Market Cap
$206.05M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$206.19M
Return on Equity (ROE)
-36.64%
TTM Avg
6.57%
3Y Avg
27.96%
5Y Avg
27.96%
Market Cap
$206.82M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$200.00M
Return on Equity (ROE)
-154.90%
TTM Avg
-136.39%
3Y Avg
-122.19%
5Y Avg
-93.38%
Market Cap
$208.37M
Return on Equity (ROE)
-71.02%
TTM Avg
-15.82%
3Y Avg
-19.73%
5Y Avg
-5.35%
Market Cap
$208.71M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
Market Cap
$211.33M
Return on Equity (ROE)
39.66%
TTM Avg
4.24%
3Y Avg
-15.88%
5Y Avg
-20.06%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $203.92M | N/A | -9.37% | -9.48% | -168.40% |
| Surrozen, Inc. (SRZN)vs › | $202.26M | N/A | 213.11% | 66.34% | 24.75% |
| Alector, Inc. (ALEC)vs › | $206.05M | N/A | -280.12% | -179.90% | -133.80% |
| Sionna Therapeutics, Inc. (SION)vs › | $206.19M | -36.64% | 6.57% | 27.96% | 27.96% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $200.00M | -154.90% | -136.39% | -122.19% | -93.38% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.37M | -71.02% | -15.82% | -19.73% | -5.35% |
| Pro-Dex, Inc. (PDEX)vs › | $208.71M | 28.68% | 26.59% | 20.62% | 19.74% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 39.66% | 4.24% | -15.88% | -20.06% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | -45.23% | -120.85% | -88.04% | -69.68% |
ROE
N/A
ROA
-48.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-09-30 | -59.94% |
| 2023-06-30 | -53.55% |
| 2023-03-31 | -20.20% |
| 2022-12-31 | 37.71% |
| 2022-09-30 | 49.14% |
| 2022-06-30 | 35.40% |
| 2022-03-31 | 49.65% |
| 2021-12-31 | -114.06% |
| 2019-12-31 | -659.16% |
| 2019-03-31 | -415.16% |
| 2018-09-30 | -702.29% |
| 2018-06-30 | -284.00% |
| 2018-03-31 | -158.90% |
| 2017-12-31 | -126.07% |
| 2017-09-30 | -91.98% |
| 2017-06-30 | -67.68% |
| 2017-03-31 | -106.76% |
| 2016-12-31 | -65.89% |
| 2016-09-30 | -44.28% |
| 2016-06-30 | -39.22% |
| 2016-03-31 | -187.68% |
